(Source: RxList – New and Updated Drug Monographs)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

{ 0 comments }

The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence.
There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice. (Source: Mass Device)

{ 0 comments }

Cassipa Approved for Opioid Dependence

September 11, 2018

MONDAY, Sept. 10, 2018 — Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release. Both buprenorphine and naloxone have been approved… (Source: Drugs.com – Daily MedNews)

Read the full article →

FDA Approves New Treatment for Opioid Dependence

September 11, 2018

MONDAY, Sept. 10, 2018 — Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release. Both buprenorphine and… (Source: Drugs.com – Pharma News) MedWorm Message: Have you tried our new medical search engine? More […]

Read the full article →

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

September 9, 2018

FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. (Source: Food and Drug Administration) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion

August 29, 2018

TUESDAY, Aug. 28, 2018 — There was an increase in buprenorphine with naloxone fills in expansion versus nonexpansion counties after Medicaid expansion, according to a study published online Aug. 17 in JAMA Network Open. Brendan Saloner, Ph.D., from… (Source: Drugs.com – Pharma News) MedWorm Message: Have you tried our new medical search engine? More powerful […]

Read the full article →

Prescriptions for opioid use disorder treatment, opioid pain relievers after ACA Medicaid expansion

August 18, 2018

(JAMA Network) Medicaid expansion under the Affordable Care Act (ACA) was associated with an overall increase   in people filling prescriptions for buprenorphine with naloxone, which is a treatment for opioid use disorder, as well as an increase in people filling prescriptions for opioid pain relievers (OPRs) paid for by Medicaid in a data analysis […]

Read the full article →

U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug

August 9, 2018

Indivior said on Monday a U.S. Court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment, Suboxone Film (buprenorphine and naloxone).Reuters Health Information (Source: Medscape Medical News Headlines)

Read the full article →

U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug

August 9, 2018

Indivior said on Monday a U.S. Court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment, Suboxone Film (buprenorphine and naloxone).Reuters Health Information (Source: Medscape Medical News Headlines)

Read the full article →

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

August 9, 2018

The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone. (Source: Reuters: Health) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →